NX1 Share Price Performance
AU$0
-0.04 (-100.00%)
Price AU$0
Share Pricen/a
Nexalis Therapeutics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
NX1 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Nexalis Therapeutics Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.0072
- 100.00%
- -238.28%
- -63.1%
About NX1
- Founded
- 2016
- Employees
- n/a
- CEO
- WebsiteView website
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.
